GST/ AEP 融合蛋白原核表达载体的构建、表达及鉴定

目的：为进一步研究抗癫痫肽（And—epilepsy peptide,AEP）的抗痫机制及筛选其相关作用蛋白,进行GST／AEP融合蛋白原核表达载体的构建及融合蛋白的表达。方法：通过PCR基因扩增对AEP基因进行扩增,并将其克隆于谷胱甘肽-S-转移酶（GST）融合蛋白表达质粒pGEX-4T-1中,经酶切、序列鉴定分析后,用该重组质粒转化大肠杆菌B121（DE3）,经IPTG诱导获得表达,并采用Western Blot进行检测。结果：成功构建了AEP原核表达载体,并在大肠杆菌B121中获得表达。结论：成功构建了GST／AEP原核表达载体,并表达了GST／AEP融合蛋白。     

磷脂酰肌醇蛋白聚糖3真核表达载体的构建及在细胞中的表达

构建载体表达人磷脂酰肌醇蛋白聚糖3(Glypican-3,GPC3)蛋白,用以获得抗GPC3单克隆抗体。用PCR技术扩增GPC3基因,利用酶切位点将该序列插入p3XFLAG-CMV-14载体,构建p CMV-gpc3表达载体。通过脂质体将该载体转染至HEK293细胞中,利用Western blot技术检测最终结果。收集稳定表达的细胞,破碎,通过亲和层析柱,获得纯度较高的GPC3蛋白。成功构建p CMV-gpc3真核表达载体,转染至HEK293细胞后,经G418筛选获得稳定表达的单克隆细胞系;Western blot分析结果表明目的蛋白高效表达。     

AA12(LG21)可溶性表达研究及抗体制备

用PCR技术从AA22基因上扩增出LG21(100—498bp)片段,并克隆到原核表达载体pET—28a( )上;转化大肠杆菌B121(DE3),进行诱导表达研究,使其在大肠杆菌中能够可溶性表达,优化表达条件获得表达量比较高的LG21蛋白;用镍离子螯和柱(Ni—NTA)纯化LG21蛋白,获得纯度较高的蛋白。用纯蛋白免疫小鼠制备多克隆抗体,ELISA结果显示效价可达到1：163 840;Westem结果表明该抗体可以与LG21蛋白特异结合;为进行免疫共沉淀实验,验证Chkl蛋白与AAl2蛋白在体内的相互作用奠定了基础。     

HER-2/neu胞外配体结合区2在大肠杆菌中可溶性表达及纯化

用PCR技术扩增HER 2 neu胞外配体结合区 2 (RLD2 )cDNA ,并将扩增的基因片段克隆于硫氧还蛋白 (TrxA)原核表达载体中 ,获得TrxA RLD2融合蛋白的可溶性表达 .通过插入偶联翻译序列 ,实现TrxA与RLD2蛋白在大肠杆菌中的共表达 .表达产物经免疫印记检测可被抗HER 2 neu特异性抗体识别 .经离子交换层析和钴亲和层析纯化 ,RLD2蛋白的纯度达 90 % .用质谱法分析RLD2蛋白的分子量 ,与预期值相符 .结果表明 ,利用TrxA表达体系在大肠杆菌中获得了HER 2 neuRLD2蛋白高效可溶性表达     

小鼠β-防御素30的原核表达和纯化

目的:在原核细胞中表达小鼠β-防御素30(DEFB30),并对表达产物进行鉴定和纯化。方法:用RT-PCR方法扩增小鼠Defb30的cDNA序列,将2个拷贝的cDNA序列串联连入原核表达载体pET28(a),构建重组表达载体pET28(a)-Defb30,并将重组表达载体转化至大肠杆菌Rosetta(DE3),IPTG诱导表达,以Western印迹分析表达产物His-DEFB30,用Ni-NTA亲和柱纯化融合蛋白。结果:构建了Defb30基因的原核表达载体,经IPTG诱导,相对分子质量约15×103的融合蛋白获得表达,Western印迹分析证实此蛋白即为目的蛋白,经Ni-NTA柱亲和纯化,获得了高纯度的融合蛋白His-DEFB30。结论:获得了在大肠杆菌中表达的DEFB30,为研究该蛋白的免疫避孕效果、抗菌活性奠定了基础。     

丙型肝炎病毒核心蛋白基因的克隆与表达

以含有丙型肝炎病毒核心蛋白基因的质粒pJLA502-C为模板,用PCR方法重新扩增克隆了核心蛋白基因,在扩增基因的上下端分别增加了NCOⅠ及SalⅠ酶切位点。将克隆的基因酶切后插入表达载体pBV221内,转化大肠肝菌DH_(5α),获得表达非融合核心蛋白的工程菌,42℃热诱导5hr,表达蛋白占菌体蛋白总量的15％。经包涵体纯化及分子筛纯化等,获得核心蛋白,经ELISA及Western Blotting分析表明有较好的抗原性和特异性。     

人谷胱甘肽硫转移酶A1在乳酸乳球菌中的表达及活性研究

用RTPCR技术从人肝总RNA中分离扩增了人谷胱甘肽硫转移酶A1基因的cDNA序列,克隆至大肠杆菌表达质粒pET23b,采用蛋白表达筛查法及DNA测序证明该cDNA序列完全正确。重组质粒pET23bhgst转化大肠杆菌BL21(DE3),经IPTG诱导获得高效表达的可溶性hGSTA1产物,其表达量约为大肠杆菌可溶性总蛋白的40%。将hGSTA1cDNA亚克隆至乳酸乳球菌表达载体pMG36e,电穿孔法转化乳酸乳球菌MG1363获得hGSTA1乳酸乳球菌表达株。SDSPAGE及Western杂交分析表明该菌株表达预期大小的hGSTA1融合蛋白,经谷胱甘肽琼脂糖亲和层析纯化获得的hGSTA1蛋白具有较高的谷胱甘肽硫转移酶活性。具hGSTA1酶活性的乳酸乳球菌工程菌可望应用于研制防癌保健乳制品。     

弓形虫GRA6蛋白和P30蛋白的融合表达、纯化及抗原性分析

利用基因工程技术制备抗原性好的弓形虫GRA6蛋白和P30蛋白的融合蛋白,并用作抗原检测弓形虫抗体。根据弓形虫GRA6蛋白和P30蛋白的氨基酸序列,通过计算机分析,筛选出其中较强的抗原决定簇。用PCR方法分别扩增含抗原决定簇的基因片段。将这两个基因片段克隆至同一质粒pET28a(+)内,表达一个融合蛋白。将重组质粒转化大肠杆菌BL21(DE3),筛选表达该融合蛋白的工程菌。纯化表达的融合蛋白,用已知的6份抗弓形虫IgM阳性血清和大量正常人血清,ELISA法检测纯化融合蛋白的抗原性和特异性。获得了高效表达含弓形虫GRA6蛋白和P30蛋白抗原表位的工程菌,表达的融合蛋白约占菌体蛋白总量的25%。纯化获得了表达的融合蛋白,该蛋白有较好的抗原性和特异性。表达的弓形虫GRA6和P30融合蛋白可用做抗原检测弓形虫抗体,用于临床及孕妇检测,对优生优育有较大意义。     

人早胚发育相关蛋白ZNF268的抗体制备

目的:获得纯化抗原用于制备ZNF268的多克隆抗体。方法:PCR扩增目的基因片Spacer区序列,亚克隆入融合蛋白表达载体pET28a+,构建了重组质粒pET28a+/SPA。然后将该重组质粒转化E.coliDE3(Rosseta),IPTG诱导表达,SDS-PAGE分离,获纯化融合蛋白6His-SPA。用6His-SPA免疫家兔,颈动脉取血,分离血清,从血清中获得ZNF268特异的多克隆抗体。结论:通过构建融合蛋白重组表达质粒pET28a+/SPA,用获得的初步纯化融合蛋白6His-SPA,制备了特异的ZNF268的多克隆抗体6His-SPA Ab。     

丝状支原体丝状亚种SC型脂蛋白Q N末端基因的表达、纯化与抗原性分析

为了表达丝状支原体丝状亚种SC型(MmmSC)中国分离株HVRIⅩ脂蛋白Q(LppQ)N末端基因,将该基因经PCR扩增后克隆至原核表达载体pET32a中,经酶切、PCR、测序证实获得了重组表达质粒,转化Escherichia coliBL21(DE3)菌,经IPTG诱导后获得可溶性融合蛋白,表达量占菌体总蛋白的53.7%,用Ni-NTAHis.Bind纯化试剂盒纯化后,蛋白纯度达95%以上。表达蛋白经Western blot检测其抗原活性,结果表明纯化蛋白可与CBPP标准阳性血清发生强烈的反应,而与阴性血清不发生反应。     

Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis

It has now been over twenty years since a novel herpesviral genome was identified in Kaposi's sarcoma biopsies. Since then, the cumulative research effort by molecular biologists, virologists, clinicians, and epidemiologists alike has led to the extensive characterization of this tumor virus, Kaposi's sarcoma-associated herpesvirus(KSHV; also known as human herpesvirus 8(HHV-8)), and its associated diseases. Here we review the current knowledge of KSHV biology and pathogenesis, with a particular emphasis on new and exciting advances in the field of epigenetics. We also discuss the development and practicality of various cell culture and animal model systems to study KSHV replication and pathogenesis.     

The structure, reproduction and taxonomy of Vidalia and Osmundaria (Rhodophyta, Rhodomelaceae)

Comprises species occurring mostly in subtidal habitats in tropical, subtropical and warm-temperate areas of the world. An analysis of the type species, V. spiralis (Sonder) Lamouroux ex J. Agardh, a species from Australia, establishes basic characters for distinguishing species in the genus. These characters are (1) branching patterns of thalli, (2) flat blades that may be spiralled on their axis, (3) width of the blade, (4) primary or secondary derivation of sterile and fertile branchlets and (5) position of sterile and fertile branchlets on the thalli. Application of the latter two characters provides an important basic method for separation of species into three major groups. Osmundaria , a genus known only in southern Australia, was studied in relation to Vidalia , and its separation from the Vidalia assemblage is not accepted. Species of Vidalia therefore are transferred to the older genus name, Osmundaria. Two new species, Osmundaria papenfussii and Osmundaria oliveae are described from Natal. Confusion in the usage of the epithet, Vidalia fimbriala Brown ex Turner has been clarified, and Vidalia gregaria Falkenberg, described as an epiphyte on Osmundaria pro/ifera Lamouroux, is revealed to be young branches of the host, Osmundaria prolifera.     

New or rare chromosome counts in Artemisia L. (Asteraceae, Anthemideae) and related genera from Kazakhstan

Fifteen chromosome counts of six Artemisia taxa and one species of each of the genera Brachanthemum, Hippolytia, Kaschgaria, Lepidolopsis and Turaniphytum are reported from Kazakhstan. Three of them are new reports, two are not consistent with previous counts and the remainder are confirmations of very scarce (one to four) earlier records. All the populations studied have the same basic chromosome number, x = 9, with ploidy levels ranging from 2x to 6x. Some correlations between ploidy level, morphological characters and distribution are noted.     

肝癌中HBV和HCV基因和抗原的分布及意义

采用原位分子杂交方法检测HCV RNA及HBV X基因;采用免疫组织化学方法研究HCV核心抗原,非结构区C33c抗原及HBxAg在肝细胞肝癌中的定位及分布.结果表明(1)HCV RNA、HBV X基因在肝细胞肝癌组织检出率分别为40%(55/136)和82%(112/136).HCV RNA定位于癌细胞的胞浆内,阳性细胞呈散在、灶状及弥漫分布三种形式;HBV X基因在肝癌细胞中的分布呈胞浆型、核型及核浆型,阳性细胞也呈上述三种分布形式;(2)HCV C33c抗原、核心抗原在肝细胞肝癌中的阳性率为81%(133/164)及86%(141/164).C33c抗原定位于癌细胞及肝细胞的胞浆内;核心抗原既定位于癌细胞核中,又可定位于胞浆中.C33c抗原阳性细胞以灶状分布为主;而核心抗原阳性细     

Selection with two alleles and complete dominance

For a plant selection model with frequency-independent viabilities, fertilities and selfing rates, it is shown that apart from global fixation, for certain parameter combinations a protected polymorphism and facultative fixation (either allele may become fixed according to initial frequencies) may both occur. Facultative fixation requires different selling rates for the dominant and recessive type. Protection of the polymorphism requires resource allocation for male and female function. In this connection the problem of purely genetically caused population extinction is discussed.
For general frequency dependence and regular segregation, the chances for establishment of a completely recessive gene are compared to those of a completely dominant gene. It is proven that the process of establishment of the recessive gene, despite a fitness advantage, may be considerably endangered by drift effects if random mating prevails. The recessive gene may reach the same effectivity in establishment as a dominant gene, only if the recessive homozygote mates exclusively with its own type during the period of establishment.